Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy.

Ran S, Huang X, Downes A, Thorpe PE.

Neoplasia. 2003 Jul-Aug;5(4):297-307.

PMID:
14511401
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model.

Zhang W, Ran S, Sambade M, Huang X, Thorpe PE.

Angiogenesis. 2002;5(1-2):35-44.

PMID:
12549858
[PubMed - indexed for MEDLINE]
3.

Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies.

Reichert F, Barak V, Tarshis M, Prindull G, Tarshis E, Ben-Ishay Z.

Eur J Haematol. 2005 Jul;75(1):41-6.

PMID:
15946309
[PubMed - indexed for MEDLINE]
5.

Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.

Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Witte L, Zhu Z.

J Biol Chem. 2003 Oct 31;278(44):43496-507. Epub 2003 Aug 12.

PMID:
12917408
[PubMed - indexed for MEDLINE]
Free Article
6.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.

PMID:
14522925
[PubMed - indexed for MEDLINE]
Free Article
7.

Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.

Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS, Brekken RA.

Mol Cancer Ther. 2009 Jul;8(7):1761-71. doi: 10.1158/1535-7163.MCT-09-0280. Epub 2009 Jun 30.

PMID:
19567820
[PubMed - indexed for MEDLINE]
Free Article
8.

Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature.

Korpanty G, Carbon JG, Grayburn PA, Fleming JB, Brekken RA.

Clin Cancer Res. 2007 Jan 1;13(1):323-30.

PMID:
17200371
[PubMed - indexed for MEDLINE]
Free Article
9.

Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.

Zhu Z, Hattori K, Zhang H, Jimenez X, Ludwig DL, Dias S, Kussie P, Koo H, Kim HJ, Lu D, Liu M, Tejada R, Friedrich M, Bohlen P, Witte L, Rafii S.

Leukemia. 2003 Mar;17(3):604-11.

PMID:
12646950
[PubMed - indexed for MEDLINE]
10.

Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.

Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE.

Cancer Res. 2000 Sep 15;60(18):5117-24.

PMID:
11016638
[PubMed - indexed for MEDLINE]
Free Article
11.

Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.

Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R.

Clin Cancer Res. 2000 May;6(5):1936-48.

PMID:
10815919
[PubMed - indexed for MEDLINE]
Free Article
12.

Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.

Li J, Huang S, Armstrong EA, Fowler JF, Harari PM.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1477-85.

PMID:
16029810
[PubMed - indexed for MEDLINE]
13.

Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach.

Pernasetti F, Nickel J, Clark D, Baeuerle PA, Van Epps D, Freimark B.

Int J Oncol. 2006 Dec;29(6):1371-9.

PMID:
17088974
[PubMed - indexed for MEDLINE]
14.

Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.

Wicki A, Rochlitz C, Orleth A, Ritschard R, Albrecht I, Herrmann R, Christofori G, Mamot C.

Clin Cancer Res. 2012 Jan 15;18(2):454-64. doi: 10.1158/1078-0432.CCR-11-1102. Epub 2011 Nov 7.

PMID:
22065082
[PubMed - indexed for MEDLINE]
Free Article
15.

The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.

Dineen SP, Sullivan LA, Beck AW, Miller AF, Carbon JG, Mamluk R, Wong H, Brekken RA.

BMC Cancer. 2008 Nov 27;8:352. doi: 10.1186/1471-2407-8-352.

PMID:
19038046
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.

Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP.

Clin Cancer Res. 2002 Aug;8(8):2714-24.

PMID:
12171905
[PubMed - indexed for MEDLINE]
Free Article
17.

Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library.

Popkov M, Jendreyko N, Gonzalez-Sapienza G, Mage RG, Rader C, Barbas CF 3rd.

J Immunol Methods. 2004 May;288(1-2):149-64.

PMID:
15183093
[PubMed - indexed for MEDLINE]
18.

Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.

Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM.

Cancer. 2000 Aug 1;89(3):488-99.

PMID:
10931447
[PubMed - indexed for MEDLINE]
19.

Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.

Landen CN Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK.

J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70.

PMID:
17077358
[PubMed - indexed for MEDLINE]
Free Article
20.

Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.

Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z.

Int J Cancer. 2002 Jan 20;97(3):393-9.

PMID:
11774295
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk